# Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel

> **NCT04471675** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 208 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Albumin-bound docetaxel

## Key facts

- **NCT ID:** NCT04471675
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-02
- **Primary completion:** 2022-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2022-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471675, "Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04471675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*